Oxetanes in Drug Discovery

July 10, 2019

Oxetanes have been employed to improve drugs’ physiochemical properties. Currently, over a dozen oxetane-containing drugs have progressed to different phases of clinical trials. Once one of them gains the FDA approval, the enthusiasm toward its utility in drug discovery will grow exponentially.

Spotlight

Nerhadou International

Nerhadou International is nutraceutical pioneer in Middle East. It was established in 1996 by former vice president of (Bristol Myers Squibb) Egypt, the Middle East & Africa. It is capitalizing on international trade experience in introducing high quality products to the Egyptian Market. Nerhadou is enforced by a group of professionals and consultants of multinational experience in both the pharmaceuticals & consumer goods industry and corporate management & finance.

OTHER WHITEPAPERS
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

A BLOCKCHAIN TO ENSURE COUNTERFEIT FREE PHARMACEUTICAL SUPPLY CHAIN

whitePaper | February 5, 2022

Essential medicine access is one of the main objectives of healthcare systems in and pharmaceutical supply chains ensure that the right amount of medicine, with acceptable quality, will reach the customers in need

Read More

Spotlight

Nerhadou International

Nerhadou International is nutraceutical pioneer in Middle East. It was established in 1996 by former vice president of (Bristol Myers Squibb) Egypt, the Middle East & Africa. It is capitalizing on international trade experience in introducing high quality products to the Egyptian Market. Nerhadou is enforced by a group of professionals and consultants of multinational experience in both the pharmaceuticals & consumer goods industry and corporate management & finance.

Events